Adial Pharmaceuticals, Inc. to acquire Azora Therapeutics, Inc.

Adial Pharmaceuticals, Inc. has agreed to acquire Azora Therapeutics, Inc. in a strategic acquisition within the Healthcare sector. The transaction was announced and completed on 11 June 2026, with both entities operating from the United States. Consideration for the deal was provided entirely through shares, although the specific value of the transaction was not disclosed to the public. This structure allows the acquiring company to integrate the target without an immediate cash outflow, while the target shareholders receive equity in the combined entity.

The deal represents a significant consolidation for the US healthcare market, bringing together two distinct pharmaceutical entities under a single ownership structure. As the transaction has already been completed, the integration phase is now underway. The transaction is subject to regulatory approval.